A Phase 3 Study of Tanezumab for Chronic Low Back Pain

Back to Search
Print
Bookmark Trial

NCT02528253

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Central Alabama Research
Birmingham, Alabama, 35209, United States
See other locations
Contact
877-355-1989
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

877-355-1989

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Low Back Pain
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

-Chronic low back pain ≥3 months in duration, Quebec Task Force in Spinal Disorders class 1 or 2, with documented history of previous inadequate treatment response to at least 3 different categories of agents commonly used and generally considered effective for the treatment of chronic low back pain.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


--Diagnosis of osteoarthritis of the knee or hip as defined by the American College of
Rheumatology (ACR) criteria.


- Subjects who have Kellgren Lawrence Grade > or =2 radiographic evidence of hip or
Grade > or=3 radiographic evidence of knee osteoarthritis will be excluded;


- History or radiographic evidence of other diseases that could confound efficacy or
safety assessments (e.g., rheumatoid arthritis).


- History or radiographic evidence of orthopedic conditions that may increase the risk
of, or confound assessment of joint safety conditions during the study.


- Signs and symptoms of clinically significant cardiac disease within 6 months of the
study (e.g., unstable angina, myocardial infarction, resting bradycardia, poorly
controlled or untreated hypertension) as defined in the protocol or subjects with any
other cardiovascular illness that in the opinion of the Investigator would render a
subject unsuitable to participate in the study


- History, diagnosis, or signs and symptoms of clinically significant neurological
disease (e.g., transient ischemic attack, stroke, peripheral or autonomic neuropathy)
as specified in the protocol


- Subjects with evidence or symptoms consistent with autonomic dysfunction (e.g.,
orthostatic hypotension and/or autonomic symptoms) as defined in the protocol.

Trial Details
Administration
The form in which the study drug will be delivered to the patient's body.
Tablets
Subcutaneous injections
Placebo
A placebo often looks like the investigational medication, but it has no active ingredient in it.
Yes addition
Trial Procedures
Electrocardiogram (ECG)
Physical examination
Keeping a diary
Questionnaire
X-rays
Vital signs and measurements
Urine test
Blood test

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Low Back PainComparison Of Celecoxib 200 Mg Bid, Loxoprofen Sodium 60 Mg Tid And Placebo In Low Back Pain In Japan
NCT00141154
  1. Funabashi-shi, Chiba
  2. Funabashi, Chiba
  3. Matsudo-shi, Chiba
  4. Fukuoka-shi, Fukuoka
  5. Chitose, Hokkaido
  6. Sapporo-shi, Hokkaido
  7. Sapporo, Hokkaido
  8. Katougun, Hyogo
  9. Kobe, Hyogo
  10. Nishinomiya, Hyogo
  11. Sagamihara-shi, Kanagawa
  12. Yokohama-shi, Kanagawa
  13. Yokohama, Kanagawa
  14. Hatogaya-shi, Saitama
  15. Kumagaya-shi, Saitama
  16. Kumagayashi, Saitama
  17. Minamisaitama-gun, Saitama
  18. Saitama-shi, Saitama
  19. Tokorozawa, Saitama
  20. Adachi-Ku, Tokyo
  21. Bunkyou-ku, Tokyo
  22. Edogawa-ku, Tokyo
  23. Itabashi-ku, Tokyo
  24. Koito-ku, Tokyo
  25. Meguro-Ku, Tokyo
  26. Nakano-ku, Tokyo
  27. Nerima-ku, Tokyo
  28. Ota-Ku, Tokyo
  29. Ota-Ku, Tokyo
  30. Setagaya-ku, Tokyo
  31. Shibuya-ku, Tokyo
  32. Shinagawa-ku, Tokyo
  33. Shinjyuku-ku, Tokyo
  34. Suginami-ku, Tokyo
  35. Sumida-ku, Tokyo
  36. Toyoshima-ku, Tokyo
  37. Chiba,
  38. Fukuoka,
  39. Fukuoka,
  40. Tokyo,
ALL GENDERS
20 Years+
years
MULTIPLE SITES
Low Back PainLong Term Safety Study of Tanezumab in Chronic Low Back Pain
NCT00924664
  1. Anniston, Alabama
  2. Hueytown, Alabama
  3. Huntsville, Alabama
  4. Mobile, Alabama
  5. Chandler, Arizona
  6. Peoria, Arizona
  7. Phoenix, Arizona
  8. Scottsdale, Arizona
  9. Tempe, Arizona
  10. Tempe, Arizona
  11. Little Rock, Arkansas
  12. Burbank, California
  13. Fresno, California
  14. Garden Grove, California
  15. La Jolla, California
  16. Los Gatos, California
  17. Oceanside, California
  18. Rancho Mirage, California
  19. Roseville, California
  20. Sacramento, California
  21. San Diego, California
  22. Upland, California
  23. Windomar, California
  24. Boulder, Colorado
  25. Colorado Springs, Colorado
  26. Stamford, Connecticut
  27. Trumbull, Connecticut
  28. Chiefland, Florida
  29. DeFuniak Springs, Florida
  30. DeLand, Florida
  31. Jacksonville, Florida
  32. Naples, Florida
  33. Orlando, Florida
  34. Pembroke Pines, Florida
  35. Pinellas Park, Florida
  36. South Miami, Florida
  37. St. Petersburg, Florida
  38. West Palm Beach, Florida
  39. Atlanta, Georgia
  40. Blue Ridge, Georgia
  41. Marietta, Georgia
  42. Boise, Idaho
  43. Evansville, Indiana
  44. Prairie Village, Kansas
  45. Topeka, Kansas
  46. Lexington, Kentucky
  47. Madisonville, Kentucky
  48. Monroe, Louisiana
  49. Baltimore, Maryland
  50. Worcester, Massachusetts
  51. Biloxi, Mississippi
  52. Jackson, Mississippi
  53. Springfield, Missouri
  54. St. Louis, Missouri
  55. St. Louis, Missouri
  56. Omaha, Nebraska
  57. Omaha, Nebraska
  58. Las Vegas,, Nevada
  59. Las Vegas, Nevada
  60. Berlin, New Jersey
  61. Willingboro, New Jersey
  62. Albuquerque, New Mexico
  63. Manlius, New York
  64. New York, New York
  65. New York, New York
  66. Rochester, New York
  67. Rochester, New York
  68. Williamsville, New York
  69. Greensboro, North Carolina
  70. Lenoir, North Carolina
  71. Raleigh, North Carolina
  72. Winston-Salem, North Carolina
  73. Cleveland, Ohio
  74. Oklahoma City, Oklahoma
  75. Oklahoma City, Oklahoma
  76. Medford, Oregon
  77. Portland, Oregon
  78. Altoona, Pennsylvania
  79. Bridgeville, Pennsylvania
  80. Duncansville, Pennsylvania
  81. Philadelphia, Pennsylvania
  82. Cranston, Rhode Island
  83. Warwick, Rhode Island
  84. Columbia, South Carolina
  85. Greer, South Carolina
  86. Rapid City, South Dakota
  87. Germantown, Tennessee
  88. Johnson City, Tennessee
  89. Austin, Texas
  90. Beaumont, Texas
  91. Beaumont, Texas
  92. Bryan, Texas
  93. Carroltown, Texas
  94. Dallas, Texas
  95. Houston, Texas
  96. Houston, Texas
  97. Houston, Texas
  98. Nassau Bay, Texas
  99. San Antonio, Texas
  100. Salt Lake City, Utah
  101. Salt Lake City, Utah
  102. Charlottesville, Virginia
  103. Norfolk, Virginia
  104. Richmond, Virginia
  105. Virginia Beach, Virginia
  106. Bellevue, Washington
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Low Back PainRandomized, Double Blind, Multicenter Study of the Safety and Efficacy of Valdecoxib 40 mg Once Daily Compared With Diclofenac 75 mg Twice Daily in Acute Low Back Pain
NCT00649610
  1. Bs. As.,
  2. Buenos Aires,
  3. Goiania, Goias
  4. Curitiba, Parana
  5. Curitiba, PR
  6. Petropolis, Rio de Janeiro
  7. Sao Paulo, SP
  8. Sao Paulo, SP
  9. Sao Paulo, SP
  10. Sao Paulo,
  11. Santiago,
  12. Bogota, D.c.
  13. Bogota D.c,
  14. Cali-valle,
  15. Cartago City, Cartago
  16. Hatillo, San Jose
  17. Quito, Pichincha
  18. Toluca, Edo. de Mexico
  19. Zapopan, Jalisco
  20. Zapopan, Jalisco
  21. Puebla,
  22. Puebla,
  23. Puebla,
  24. Lima,
  25. Lima,
  26. Caracas, DF
  27. Caracas, DF
  28. Caracas, DF
  29. Caracas,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Low Back PainA Study of Tanezumab in Adults With Chronic Low Back Pain
NCT00876187
  1. Anniston, Alabama
  2. Hueytown, Alabama
  3. Mobile, Alabama
  4. Chandler, Arizona
  5. Peoria, Arizona
  6. Phoenix, Arizona
  7. Phoenix, Arizona
  8. Scottsdale, Arizona
  9. Tempe, Arizona
  10. Tempe, Arizona
  11. Tucson, Arizona
  12. Little Rock, Arkansas
  13. Burbank, California
  14. Fresno, California
  15. Garden Grove, California
  16. La Jolla, California
  17. Los Gatos, California
  18. Oceanside, California
  19. Rancho Mirage, California
  20. Roseville, California
  21. Sacramento, California
  22. San Diego, California
  23. Upland, California
  24. Windomar, California
  25. Stamford, Connecticut
  26. Trumbull, Connecticut
  27. Chiefland, Florida
  28. DeFuniak Springs, Florida
  29. DeLand, Florida
  30. Fort Lauderdale, Florida
  31. Jacksonville, Florida
  32. Naples, Florida
  33. Orlando, Florida
  34. Pembroke Pines, Florida
  35. Pinellas Park, Florida
  36. South Miami, Florida
  37. St. Petersburg, Florida
  38. West Palm Beach, Florida
  39. Atlanta, Georgia
  40. Blue Ridge, Georgia
  41. Marietta, Georgia
  42. Boise, Idaho
  43. Evansville, Indiana
  44. Overland Park, Kansas
  45. Prairie Village, Kansas
  46. Topeka, Kansas
  47. Lexington, Kentucky
  48. Madisonville, Kentucky
  49. Monroe, Louisiana
  50. Baltimore, Maryland
  51. Worcester, Massachusetts
  52. Lansing, Michigan
  53. Biloxi, Mississippi
  54. Jackson, Mississippi
  55. St. Louis, Missouri
  56. Omaha, Nebraska
  57. Omaha, Nebraska
  58. Las Vagas, Nevada
  59. Las Vegas, Nevada
  60. Berlin, New Jersey
  61. Willingboro, New Jersey
  62. Albuquerque, New Mexico
  63. Manlius, New York
  64. New York, New York
  65. New York, New York
  66. Rochester, New York
  67. Rochester, New York
  68. Williamsville, New York
  69. Greensboro, North Carolina
  70. Lenoir, North Carolina
  71. Raleigh, North Carolina
  72. Winston-Salem, North Carolina
  73. Cincincinati, Ohio
  74. Cincinnati, Ohio
  75. Cleveland, Ohio
  76. Oklahoma City, Oklahoma
  77. Oklahoma City, Oklahoma
  78. Medford, Oregon
  79. Portland, Oregon
  80. Altoona, Pennsylvania
  81. Bethlehem, Pennsylvania
  82. Bridgeville, Pennsylvania
  83. Duncansville, Pennsylvania
  84. Philadelphia, Pennsylvania
  85. Cranston, Rhode Island
  86. Warwick, Rhode Island
  87. Columbia, South Carolina
  88. Greer, South Carolina
  89. Rapid City, South Dakota
  90. Germantown, Tennessee
  91. Johnson City, Tennessee
  92. Austin, Texas
  93. Austin, Texas
  94. Beaumont, Texas
  95. Bryan, Texas
  96. Carroltown, Texas
  97. Houston, Texas
  98. Houston, Texas
  99. Houston, Texas
  100. Houston, Texas
  101. Nassau Bay, Texas
  102. San Antonio, Texas
  103. San Antonio, Texas
  104. Salt Lake City, Utah
  105. Salt Lake City, Utah
  106. Charlottesville, Virginia
  107. Norfolk, Virginia
  108. Richmond, Virginia
  109. Virginia Beach, Virginia
  110. Bellevue, Washington
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE A Phase 3 Study of Tanezumab for Chronic Low Back Pain
Official Title  ICMJE A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO AND ACTIVE-CONTROLLED, MULTICENTER, PARALLEL-GROUP STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB IN ADULT SUBJECTS WITH CHRONIC LOW BACK PAIN
Brief Summary This study will investigate the efficacy and safety of tanezumab 5 mg and 10 mg administered by subcutaneous injection seven times at 8 week intervals (56 weeks). The primary objective of this study is to evaluate the effectiveness of tanezumab 10 mg and 5 mg compared to placebo for the treatment of chronic low back pain. Secondary objectives are to evaluate the long-term safety and effectiveness of tanezumab 10 mg and 5 mg compared to placebo for the treatment of chronic low back pain. In addition, the study will evaluate the effectiveness and long term safety profile of tanezumab treatment for chronic low back pain compared to tramadol Prolonged Release (PR), a medication commonly utilized for the treatment of chronic low back pain.
Detailed Description This is a randomized, double blind, placebo and active controlled, multicenter, parallel group Phase 3 study of the efficacy and safety of tanezumab when administered by SC injection for up to 56 weeks in subjects with chronic low back pain. Approximately 1800 subjects will be randomized to 1 of 4 treatment groups in a 2:2:2:3 ratio (ie, 400 subjects per treatment group for the placebo, tanezumab 5 mg and tanezumab 10 mg treatment groups and 600 subjects in the tramadol PR treatment group). Treatment groups will include: 1.) Placebo administered SC at an 8 week interval plus placebo matching tramadol PR up to Week 16. At the Week 16 visit, subjects in this group who meet the efficacy responder criteria will be switched in a blinded fashion in a 1:1 ratio to either tanezumab 5 mg or tanezumab 10 mg administered SC at an 8 week interval plus placebo matching tramadol PR to Week 56; 2.)Tanezumab 5 mg SC administered at an 8 week interval plus placebo matching tramadol PR to Week 56; 3.) Tanezumab 10 mg SC administered at an 8 week interval plus placebo matching tramadol PR to Week 56; 4.) Oral tramadol PR plus placebo administered SC at an 8 week interval to Week 56. The study is designed with a total duration (post randomization) of up to 80 weeks and will consist of three periods: Screening (up to a maximum of 37 days; includes a Washout Period and an Initial Pain Assessment Period), a Double blind Treatment Period (comprised of a 16 week Primary Efficacy Phase and a 40 week Long Term Safety and Efficacy Phase), and a Follow up Period (24 weeks). The Screening Period (beginning up to 37 days prior to Randomization) includes a Washout Period (lasting 2 32 days), if required, and an Initial Pain Assessment Period (the 5 days prior to Randomization/Baseline). Prior to entering the study, subjects must have a documented history of previous inadequate treatment response to medications in 3 different categories of agents commonly used to treat and generally considered effective for the treatment of chronic low back pain.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Low Back Pain
Intervention  ICMJE
  • Biological: Placebo to Week 16; tanezumab 5mg SC
    Placebo SC injection every 8 weeks for 2 injections followed by tanezumab 5 mg injection every 8 weeks for 5 injections
  • Biological: Placebo to Week 16, tanezumab 10 mg SC
    Placebo SC injection every 8 weeks for 2 injections, followed by tanezumab 10 mg SC injection for 5 injections
  • Biological: Tanezumab 5 mg SC
    Tanezumab 5 mg SC
  • Biological: Tanezumab 10 mg SC
    Tanezumab 10 mg SC
  • Biological: Tramadol PR oral
    Tramadol PR oral
Study Arms  ICMJE
  • Placebo Comparator: Placebo to Week 16; tanezumab 5 mg SC
    Intervention: Biological: Placebo to Week 16; tanezumab 5mg SC
  • Placebo Comparator: Placebo to Week 16, tanezumab 10 mg SC
    Intervention: Biological: Placebo to Week 16, tanezumab 10 mg SC
  • Experimental: Tanezumab 5 mg SC
    Intervention: Biological: Tanezumab 5 mg SC
  • Experimental: Tanezumab 10 mg SC
    Intervention: Biological: Tanezumab 10 mg SC
  • Active Comparator: Tramadol PR oral
    Intervention: Biological: Tramadol PR oral
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: February 25, 2019)		1832
Original Estimated Enrollment  ICMJE
 (submitted: August 18, 2015)		1800
Actual Study Completion Date  ICMJE December 20, 2018
Actual Primary Completion Date October 17, 2017   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

-Chronic low back pain ?3 months in duration, Quebec Task Force in Spinal Disorders class 1 or 2, with documented history of previous inadequate treatment response to at least 3 different categories of agents commonly used and generally considered effective for the treatment of chronic low back pain.

Exclusion Criteria:

--Diagnosis of osteoarthritis of the knee or hip as defined by the American College of Rheumatology (ACR) criteria.

  • Subjects who have Kellgren Lawrence Grade > or =2 radiographic evidence of hip or Grade > or=3 radiographic evidence of knee osteoarthritis will be excluded;
  • History or radiographic evidence of other diseases that could confound efficacy or safety assessments (e.g., rheumatoid arthritis).
  • History or radiographic evidence of orthopedic conditions that may increase the risk of, or confound assessment of joint safety conditions during the study.
  • Signs and symptoms of clinically significant cardiac disease within 6 months of the study (e.g., unstable angina, myocardial infarction, resting bradycardia, poorly controlled or untreated hypertension) as defined in the protocol or subjects with any other cardiovascular illness that in the opinion of the Investigator would render a subject unsuitable to participate in the study
  • History, diagnosis, or signs and symptoms of clinically significant neurological disease (e.g., transient ischemic attack, stroke, peripheral or autonomic neuropathy) as specified in the protocol
  • Subjects with evidence or symptoms consistent with autonomic dysfunction (e.g., orthostatic hypotension and/or autonomic symptoms) as defined in the protocol.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Canada,   Denmark,   France,   Hungary,   Japan,   Korea, Republic of,   Spain,   Sweden,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02528253
Other Study ID Numbers  ICMJE A4091059
2012-005495-34 ( EudraCT Number )
CLBP SC STUDY ( Other Identifier: Alias Study Number )
A4091059 ( Other Identifier: Pfizer )
TANGO ( Other Identifier: Alias Study Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD:Yes
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d….
URL:https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d…
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Eli Lilly and Company
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date February 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP